WASHINGTON -- Extended pelvic lymph node dissection (ePLND) after radical prostatectomy failed to improve survival in intermediate- and high-risk prostate cancer over standard lymphadenectomy, ...
PSMA-PET could be considered in selective cases, given its modest sensitivity and prognostic value in intermediate-risk prostate cancers. All evaluated staging modalities for detecting lymph node ...
According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...
Learn how prostate cancer is treated at each stage, from active surveillance and surgery to radiation, hormone therapy, and targeted drugs.
Fifteen-year outcomes of external radiation with or without 6 months of neoadjuvant deprivation therapy for intermediate risk prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data. Anatomical location of ...
A case report led by UCLA Health researchers highlights the importance of a multidisciplinary, evidence-based approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results